Rege Nephro Co., Ltd. is a clinical-stage biotech company developing treatments for kidney diseases, including Autosomal Dominant Polycystic Kidney Disease and Chronic Kidney Disease, using technology from Kyoto University's Center for iPS Cell Research and Application.